Antibodies in the prevention of renal allograft rejection

Bibliography

• LECHLER RI, LOMBARDI G, BATCHELOR JR, REINSMOEN N, BACH F: The molecular basis of alloreactivity. Inonunol. Today (1990) 11(3):83–88.
   PubMedGoogle Scholar
• SAYEGH MH, WATSCHINGER B, CARPENTER C: Mechanisms of T cell recognition of alloantigen. The role of peptides. Transplantation (1994) 57(9):1295–1302.
   PubMedGoogle Scholar
• SAYEGH MH, TURKA L: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl. J. Med. (1998) 338:1813–1821.
   PubMed Web of Science ®Google Scholar
• GIMMI CD, FREEMAN GJ,GRIBBEN JG, GRAY G, NADLER L: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Nati Acad. Sci. USA (1993) 90(14):6586–6590.
   PubMed Web of Science ®Google Scholar
• NOEL PJ, BOISE LH, GREEN JM, THOMPSON C: CD28 costimulation prevents cell death during primary T cell activation.' hionunol. (1996) 157(2):636–642.
   Google Scholar
• SHEIL AG, KELLY GE, STOREY BG et al.: Controlled clinical trial of antilymphocyte globulin in patients with renal allografts from cadaver donors. Lancet (1971) 1(7695):359–363.
   PubMed Web of Science ®Google Scholar
• HOWARD RJ, CONDIE RM, SUTHERLAND DE, SIMMONS RL, NAJARIAN J: The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study. Transplantation (1977) 24(6):419–423.
   PubMed Web of Science ®Google Scholar
• COSIMI AB, BURTON RC, COLVIN RB et al.: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 32(6):535–539.
   PubMed Web of Science ®Google Scholar
• ORTHO MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. OrthoMulticenter Transplant Study Group. N Engl. Med. (1985) 313(6):337–342.
   PubMed Web of Science ®Google Scholar
• STARZL TE, MARCHIORO TL, HUTCHINSON DE, PORTER KA, CERILLI GJ, BRETTSCHNEIDER L: The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation (1967) 5(4 Suppl.):1100–1105.
   Google Scholar
• DEODHAR SD, KONOMI K, NAKAMOTO S, KURUVILA K: Clinical experience with antilymphocyte globulin (ALG) in renal transplantation. Transplant. Proc. (1971) 3(1):758–761.
   PubMed Web of Science ®Google Scholar
• BIRTCH AG, CARPENTER CB, TILNEY NL et al.: Controlled clinical trial of antilymphocyte globulin in human renal allografts. Transplant. Proc. (1971) 3(1):762–765.
   PubMed Web of Science ®Google Scholar
• NOVICK AC, BRAUN WE, STEINMULLER D, BUSZTA C, GREENSTREET R, KISER W: Controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation. Transplantation (1983) 35(2):175–179.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE S: Antithymocyte globulin in renal transplant recipients. Report of a prospective randomized controlled trial. Arch. Surg. (1976) 111(6):680–683.
   Google Scholar
• WECHTER WJ, BRODIE JA, MORRELL RM, RAFI M, SCHULTZ J: Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation (1979) 28(4):294–302.
   Google Scholar
• BELL PR, BLAMEY RW, BRIGGS JD et al.: Medical research council trial of antilymphocyte globulin in renal transplantation. A multicenter randomized double-blind placebo controlled clinical investigation. Transplantation (1983) 35(6):539–545.
   Google Scholar
• MICHAEL HJ, FRANCOS GC, BURKE JF et al.: A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation (1989) 48(5)805–808.
   Google Scholar
• BELITSKY P, MACDONALD AS, COHEN AD et al.: Comparison of antilymphocyte globulin and continuous i.v. cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplant. Proc. (1991) 23(1 Pt 2):999–1000.
   Google Scholar
• BANHEGYI C, ROCKENSCHAUB S, MUHLBACHER F et al.: Preliminaryresults of a prospective randomized clinical trial comparing cyclosporine A to antithymocyte globulin immunosuppressive induction therapy in kidneytransplantation. Transplant. Proc. (1991) 23(4):2207–2208.
   PubMed Web of Science ®Google Scholar
• HURAULT DE, LIGNY B, LEBRANCHU Y: The use of thymoglobuline induction in renal transplantation: a pharmacovigilance study. Transplant. Proc. (2000) 32(2):351–352.
   PubMed Web of Science ®Google Scholar
• LEBRANCHU Y, BRIDOUX F, BUCHLER M et al.: Immunoprophylaxiswith basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Ain. Transplant. (2002) 2(1):48–56.
   PubMed Web of Science ®Google Scholar
• WILDE MI, GOA K: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs (1996) 51(5):865–894.
   PubMed Web of Science ®Google Scholar
• •Excellent review of OKT3 and its side effects.
   Google Scholar
• NORMAN DJ, KAHANA L, STUART FP JR et al.: A randomizedclinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation (1993) 55(1):44–50.
   Google Scholar
• ABRAMOWICZ D, GOLDMAN M, DE PAUW L, VANHERWEGHEM JL, KINNAERT P, VEREERSTRAETEN P: The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation (1992) 54(3):433–437.
   PubMed Web of Science ®Google Scholar
• ABRAMOWICZ D, NORMAN DJ, GOLDMAN M et al.: OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant. Proc. (1995) 27(1):852–853.
   PubMed Web of Science ®Google Scholar
• SPANISH MONOTHERAPY STUDY GROUP: Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group. Transplant. Proc. (1994) 26(5):2522–2524.
   Google Scholar
• SHIELD CF, EDWARDS EB,DAVIES DB, DAILY 0: Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study [comment]. Transplantation (1997) 63(9):1257–1263.
   PubMed Web of Science ®Google Scholar
• ABRAMOWICZ D, SCHANDENE L, GOLDMAN M et al.: Release of tumor 250 necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation (1989) 47(4):606–608.
   PubMed Web of Science ®Google Scholar
• NORMAN DJ, CHATENOUD L, COHEN D, GOLDMAN M, SHIELD CF 3RD: Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant. Proc. (1993) 25(2 Suppl. 1):89–92.
   Google Scholar
• THISTLETHWAITE JR JR, STUART JK, MAYES JT et al.: Complications and monitoring of OKT3 therapy. Am. Kidney Dis. (1988) 11(2):112–119.
   PubMed Web of Science ®Google Scholar
• CHATENOUD L: Humoral immune response against OKT3. Transplant. Proc. (1993) 25(2 Suppl. 1):68–73.
   Google Scholar
• SZCZECH L, BERLIN J, ARADHYE S, GROSSMAN R, FELDMAN H: Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. Am. Soc. Nephrol. (1997) 8(11):1771–1777.
   PubMed Web of Science ®Google Scholar
• •Systematic review of antilymphocyte antibodies in renal transplantation.
   Google Scholar
• SLAKEY DP, JOHNSON CP, CALLALUCE RD et al.: A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function. Transplantation (1993) 56(4):827–831.
   PubMed Web of Science ®Google Scholar
• SZCZECH LA, BERLIN JA, FELDMAN HI: The effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis of individual patient-level data. Ann. Intern. Med. (1998) 128(10):817–826.
   PubMed Web of Science ®Google Scholar
• •Long-term systematic review of antilymphocyte antibodies in renal transplantation using individual patient data.
   Google Scholar
• MEIER-KRIESCHE HU,ARNDORFER JA, KAPLAN B: Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. Am. Soc. Nephrol. (2002) 13(3):769–772.
   PubMedGoogle Scholar
• •Good registry study of complications of antibody induction.
   Google Scholar
• HIBBERD PL, TOLKOFF-RUBIN NE, COSIMI AB et al.: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation (1992) 53(1):68–72.
   PubMed Web of Science ®Google Scholar
• NASHAN B, LUCK R, KLIEM V, BRUNKHORST R, SCHLITT HJ,KLEMPNAUER J: CMV in kidney transplantation: a single center experience over 22 years. Clin. Transpl. (1999):181–188.
   PubMedGoogle Scholar
• MELOSKY B, KARIM M, CHUI A et al.: Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J. Am. Soc. Nephrol. (1992) 2(12 Suppl.):S290–S294.
   Google Scholar
• COCKFIELD SM, PREIKSAITIS JK, JEWELL LD, PARFREY N: Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation (1993) 56(1):88–96.
   Google Scholar
• WALDMANN T: The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today(1993) 14(6):264–270.
   PubMedGoogle Scholar
• ••Excellent review of the IL-2 receptor andthe development of blocking antibodies.
   Google Scholar
• THEZE J, ALZARI PM, BERTOGLIO J: Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today (1996) 17(10):481–486.
   PubMedGoogle Scholar
• •Review of the structure and function of the IL-2 receptor.
   Google Scholar
• WALDMANN TA, O'SHEA J: The use of antibodies against the IL-2 receptor in transplantation. Can: Opin. Immunol. (1998) 10(5):507–512.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JA, BACON CM, FINBLOOM DS et al.: Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Nati Acad. Sci. USA (1995) 92(19):8705–8709.
   PubMed Web of Science ®Google Scholar
• SOULILLOU JP, PEYRONNET P, LE MAUFF B et al.: Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet (1987) 1(8546):1339–1342.
   Google Scholar
• SOULILLOU JP, CANTAROVICH D, LE MAUFF B et al.: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts [comment]. N Engl. I Med. (1990) 322(17):1175–1182.
   Google Scholar
• KIRKMAN R, BARRETT L,CARPENTER C et al.: A randomised trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation (1991) 51:107–113.
   Google Scholar
• VAN GELDER T, ZIETSE R, MULDER A et al.: A double blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation (1995) 60:248–252.
   PubMed Web of Science ®Google Scholar
• KOVARIK J, WOLF P, CISTERNE JM et al.: Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation (1997) 64(12):1701–1705.
   PubMed Web of Science ®Google Scholar
• NASHAN B, MOORE R,SCHMIDT A-G, ABEYWICKRAMA K, SOULILLOU J-P: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet (1997) 350:1193–1198.
   PubMed Web of Science ®Google Scholar
• KAHAN B, RAJAGOPALAN P, HALL M: Reduction of the occurence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation (1999) 67:276–284.
   PubMed Web of Science ®Google Scholar
• LAWEN J, DAVIES E, MORAD F et al.: Basiliximab (Simulect) is safe and effective in combination with triple therapy of Neoral, steroids and cellcept in renal transplant recipients. Transplantation (2000) 69:S260.
   Web of Science ®Google Scholar
• PONTICELLI C, YUSSIM A, CAMBI V et al.: A randomised double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 72:1261–1267.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl. I Med. (1998) 338:161.
   PubMed Web of Science ®Google Scholar
• NASHAN B, LIGHT S, HARDIE I, LIN A, JOHNSON J: Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation (1999) 67:110–115.
   PubMed Web of Science ®Google Scholar
• ADU D, COCKWELL P, IVES NJ, SHAW J, WHEATLEY K: Interleuldn-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Br. Med.' (2003) 326(7393):12.
   Google Scholar
• •Systematic review of IL-2 receptor antibody trials in renal transplantation.
   Google Scholar
• MATAS AJ, GILLINGHAM KJ,PAYNE WD, NAJARIAN J: The impact of an acute rejection episode on long-term 251renal allograft survival (t1/2). Transplantation (1994) 57(6):857–859.
   PubMed Web of Science ®Google Scholar
• HARIHARAN S, JOHNSON C, BRESNAHAN B, TARANTO S, MCINTOSH M, STABLEIN D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl. Med. (2000) 342:605–612.
   PubMed Web of Science ®Google Scholar
• SHEASHAA HA, BAKR MA,ISMAIL AM, SOBH MA, GHONEIM M: Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J. Nephrol (2003) 16(3):393–398.
   PubMed Web of Science ®Google Scholar
• SOLLINGER H, KAPLAN B,PESCOVITZ MD et al.: Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation (2001) 72(12):1915–1919.
   Google Scholar
• BRENNAN DC, GROUP TIS:In: The Fourth American Transplant Meeting Program and Abstracts of American Transplant Meeting, Washington DC, USA (2003) Abstract 1121.
   Google Scholar
• SPRINGER T: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76(2):301–314.
   PubMed Web of Science ®Google Scholar
• SALMELA K, WRAMNER L, EKBERG H et al.: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation (1999) 67(5):729–736.
   PubMed Web of Science ®Google Scholar
• HOURMANT M, BEDROSSIAN J, DURAND D et al.: Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplant. Proc. (1995) 27(1):864.
   PubMed Web of Science ®Google Scholar
• VINCENTI F: What's in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant. (2002) 2(10):898–903.
   PubMed Web of Science ®Google Scholar
• KIRK AD, BURKLY LC, BATTY DS et a/.: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (1999) 5(6):686–693.
   Google Scholar
• KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI A: Thromboembolic complications after treatment with monoclonal antibodyagainst CD40 ligand. Nat. Med. (2000) 6(2):114.
   Web of Science ®Google Scholar
• KALUNIAN KC, DAVIS JC JR, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritic Rheum. (2002) 46(12):3251–3258.
   PubMed Web of Science ®Google Scholar
• CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68(10):1613–1616.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/cber/products/ daclhof121097.htm US FDA Center for Biologics Evaluation and Research website.Affiliation
   Google Scholar